Mycobacterial Diseases

Mini Review

Mycobacterial Excretory Secretory-31 (ES-31) Protein with Serine Protease and Lipase Activities- A Potential Drug Target against TB Infection

Gauri Wankhade1, Pranita Waghmare1, Lingaraja Jena1 and Bhaskar C Harinath1*

1Bioinformatics Centre, MGIMS, Sevagram, Maharashtra, India
2Biochemistry, MGIMS, Sevagram, Maharashtra, India
3JBTDRC, MGIMS, Sevagram, Maharashtra, India

Corresponding author: BC Harinath, Director, JB Tropical Disease Research Centre, Mahatma Gandhi Institute of Medical Sciences, Sevagram–442 102, Wardha, Maharashtra, India, Tel: +91 7152-284341; Fax: (07152) 284038; E-mail: bc_harinath@yahoo.com

Rec date: August 08, 2016; Acc date: September 10, 2016; Pub date: September 16, 2016

Abstract

Tuberculosis is the second leading cause of death worldwide. The researchers still finding way to eradicate TB. There is an urgent need to discover new drug which is more effective and less toxic to combat drug resistance. This article reports potential of ES-31 antigen as a new drug target. The characterization of ES-31 antigen showed that ES-31 is a 31 kDa protein antigen and has serine protease as well as lipase activities and shown to be a chymotrypsin-like protein which is having catalytic triad responsible for both activities. Addition of serine protease inhibitors (53-76%), metallo protease inhibitor (46-61%), lipase inhibitor (61%) or anti-ES-31 serine protease antibody (89%) strongly inhibited the MTB H37Ra growth in axenic culture. The importance of excretory secretory ES-31 antigen for the survival of MTB H37Ra and H37Rv bacilli has been shown by 77% and 78% growth inhibition in macrophage culture by protease inhibitor peflabc. Inhibition of ES-31 leads to growth inhibition of MTB bacilli, suggests that it may be an important drug target for exploring new drugs for tuberculosis.

Keywords: Excretory secretory protein antigens; ES-31; Drug target; Serine protease; Lipase

Introduction

Tuberculosis (TB) has been the major cause of morbidity and mortality throughout the world. Even after declaration of TB as a global emergency by World Health Organization in 1993, it continues to be serious health problem with 9.6 million new patients and 1.5 million deaths reported in the year 2014 including 0.4 million deaths among human immunodeficiency virus (HIV) positive individuals [1]. The major problems responsible for the dreadful situation are lack of precise diagnosis and failure in control program for various reasons.

Although the existing drug treatment has immense value in controlling the disease. It also has some pitfalls, major being “drug resistance in tuberculosis”. Increasing resistance to anti-tuberculosis drugs has driven the urge for developing new drugs. Prophylactic BCG vaccine failed to reduce the prevalence of infection in adults in the countries where the disease is endemic [2]. Most available ant mycobacterial drugs do not act upon latent forms of Bacillus. HIV-TB co-infection is again the complication which adds a new challenge in TB control and hence there is need for more effective and less toxic drugs. Unexpectedly development of new anti-TB drugs with good therapeutic or prophylactic potential has not been progressed, though there is urgent need to prevent mortality and morbidity related to tuberculosis.

Mycobacterium tuberculosis bacilli are known to secrete number of proteins which play important role in pathogenicity and also have been explored for prophylactic and diagnostic usefulness. In Mycobacterium tuberculosis, conserved general secretion (Sec) and twin-arginine translocation (Tat) the two pathways perform the major protein export, it also possess specific pathway for specific subset of proteins. The export of protein is essential for MTB growth and survival. Targeting SecA2, ESX and ESX3 pathways will lead to development of new drug against TB [3]. The most popular group of secreted proteins of Mycobacterium tuberculosis is Ag 85 complex. The role of these proteins is being illustrated as essential aspect of immune response after infection, development of protective immunity and in complications of the disease [4]. For more than two decades, our laboratory has been actively involved in immune screeing of both pulmonary and extra pulmonary tuberculosis using various ES proteins. In this context many excretory secretory proteins were isolated, characterized and were being evaluated for serological diagnosis routinely in 1000 bedded Kasturba Hospital attached to Mahatma Gandhi Institute of Medical Science. ES-31, ES-41, ES-43, ES-6, ES-20, ES-100 and EST-6 [5-7] are extensively being studied and found to be essential in screening suspected cases of tuberculosis infection. Among all these proteins, ES-31 protein was observed to be a good immunogenic and diagnostic marker in pulmonary and extra pulmonary tuberculosis [8,9]. Further, ES-31 protein showed serine protease and lipase activities with good drug target potential [10,11].

Isolation and Characterization of ES-31 Antigen

M. tuberculosis H37Ra bacilli were grown in thyrone supplemented Sauton medium for 10 days to obtain culture filtrate proteins [12]. ES-31 was isolated by ammonium sulphate precipitation followed by SDS-PAGE and FPLC cation exchange [13]. ES-31 can also be isolated by affinity chromatography using anti ES-31 antibody (raised in goat) coupled to the Sepharose 4B column (1 cm) [13]. In short, culture filtrate protein (1 mg) was applied to the column and washed with 0.01 M phosphate buffer saline (PBS pH 7.2). Bound
ES-31 serine protease was eluted with Glycine-HCl buffer (0.01 M, pH 2.5), neutralized with Tris-HCl buffer (0.01 M, pH 8.6), concentrated and stored at -20°C [13]. ES-31 showed protease activity under non reducing conditions using 10% SDS-PAGE gels copolymerized with 0.1% bacteriological gelatin [13]. ES-31 has also shown to have zinc containing serine protease activity using azocasein as a substrate at pH 7.5 [13,14].

**Drug Target Potential of ES-31**

**In-vitro studies**

Confirmation of metallo serine protease activity was demonstrated by enzyme inhibition studies. In azocasein assay as shown in Table 1, serine protease inhibitor inhibited the serine protease activity i.e., 92% by 0.5 mM Pefabloc, 90% by 0.1 mM 3,4 dichloroisocoumarin and 90% by 1 mM PMSF and metallo protease inhibitors i.e., 65% inhibition by 1 mM EDTA and 78% by 0.1 mM 1,10 phenanthroline [14].

**Table 1:** Units of activity represent A440_1000/mg protein/min, b Serine protease inhibitors, c Metalloprotease inhibitors.

| Inhibitor                        | Optimum concentration | ES-31 serine protease activity (units/mg protein)a | (% inhibition) |
|----------------------------------|-----------------------|---------------------------------------------------|----------------|
| Control                          | -                     | 17.5                                              |                |
| Pefablocb                        | 0.5 mM                | 1.4 (92)                                          |                |
| 3,4 dichloroisocoumarinb         | 0.1 mM                | 1.75 (90)                                         |                |
| Phenyl methyl sulfonyl fluoride (PMSF) b | 1 mM                  | 3.50 (80)                                         |                |
| Ethylene diamine tetracetic acid (EDTA) c | 1 mM                | 6.125 (65)                                       |                |
| 1,10 phenanthroline c            | 0.5 mM                | 3.85 (78)                                         |                |
| Isoniazid                        | 0.2 mg/ml             | 0.88 (95)                                         |                |
| Anti-ES-31 serine protease antibody | 100 mg               | 0.70 (96)                                         |                |

As it was hypothesized that chymotrypsin-like proteases possess both serine protease as well as lipase activity with the specific catalytic triad present in the active site of the enzyme [15-17]. We observed that ES-31, a serine protease also has lipase activity shown by titrimetric assay [10]. ES-31 showed presence of 44.5 U/mg pr of lipase activity. The lipase activity of ES-31 was 100% inhibited by serine protease and metallo protease inhibitors (PMSF (1 mM) and EDTA (1 mM)) as well as lipase inhibitor (Orlistat). The inhibition of serine protease activity by lipase inhibitor i.e., 1 mM Orlistat was found to be 89.4%, suggesting common active site for serine protease as well as lipase activity of ES-31 thus with drug target potential. Thus ES-31 antigen is having a catalytic triad which is responsible for its serine protease as well as lipase activity and ES-31 can be categorized as a chymotrypsin-like enzyme [10].

We tried to evaluate the effect of isoniazid and orlistat in different combination of concentrations in order to check the synergistic effect. Orlistat (250 ng/ml) and isoniazid (200 ng/ml) combination showed maximum inhibition of 86% in vitro while 73% inhibition was observed by combination of orlistat (250 ng/ml) and isoniazid (200 ng/ml) on bacterial growth in axenic culture [18,19]. Orlistat can be served as an alternative to isoniazid in isoniazid resistance or intolerance cases due to its significant inhibitory action on MTB Bacilli. Whereas, inhibition MTB H37 Ra and MTB H37 Rv growth by 0.01 mM Pefabloc by 77% and 78% respectively in macrophage culture [14].

**In-vivo studies**

Addition of serine protease inhibitors (53%-76%) or metallo protease inhibitor (46%-61%) or anti-ES-31 serine protease antibody (89%) strongly inhibited the mycobacterial growth in MTB cell culture (Table 2). 0.01 mM Pefabloc (76%) showed maximum inhibition of MTB H37 Ra growth was in axenic culture (Table 2). Lipase inhibitor orlistat showed maximum 61% inhibition of MTB H37Ra bacilli in axenic culture [18,19]. Whereas, inhibition of MTB H37 Ra growth by 0.01 mM Pefabloc by 77% in macrophage culture. Further extended study of MTB H37Rv Bacilli culture showed maximum inhibition by 0.01 mM Pefabloc by 78% in macrophage culture. This study shows the importance of secretion of ES-31 antigen in the survival of the bacilli and growth [14]. Figure 1 illustrates how addition of ES-31 to macrophage culture had enhanced the entry of Bacilli and their multiplication in human macrophages [14].

| Inhibitor                        | Optimum Concentration | Concentration of ES-31 serine protease | M. tuberculosis H37Ra CFU/d Count | (% inhibition of secretion) | (% growth inhibition) |
|----------------------------------|-----------------------|---------------------------------------|----------------------------------|-----------------------------|------------------------|
| Control                          | -                     | 75 ng                                 | 16X10^5                          |                             |                        |
| Pefabloc^a                       | 0.1 mM                | 15 ng (80)                            | 3.8 X 10^5 (76)                  |                             |                        |
| 3,4 dichloroisocoumarin^a         | 0.02 mM               | 25 ng (67)                            | 7.6 X 10^5 (53)                  |                             |                        |
| Phenyl methyl sulfonyl fluoride (PMSF)^a | 0.2 mM             | 30 ng (60)                            | 7.2 X 10^4 (55)                  |                             |                        |
| Ethylene diamine tetracetic acid (EDTA)^a | 0.1 mM       | 40 ng (47)                            | 8.6 X 10^6 (46)                  |                             |                        |
Conclusion

The data suggests that ES-31 antigenic protein with protease and lipase activities can be targeted by many drugs as in-vitro and in-vivo studies so that it can have good drug target potential and also suggest that it may help in the replacement of routinely used anti-TB drugs in resistant cases in particular.

References

1. World Health Organization (2014) WHO Global Tuberculosis Report 2014. World Health Organization, Geneva, Switzerland.
2. Vasconcelos-junior AC, de Araujo-Filho JA, da Silva EB, de Sousa EM, Kipnis A, et al. (2009) Limitations of the BCG vaccine and new prophylaxis strategies against human tuberculosis. Einstein 7: 383-389.
3. Feltcher ME, Sullivani JT, Braunstein M (2010) Protein export systems of Mycobacterium tuberculosis: novel targets for drug development? Future Microbiol 5: 1581-1597.
4. Wiker HG, Harboe M (1992) The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiological reviews 56: 648-661.
5. Majumdar A, Thamke D, Mendiratta DK, Harinath BC (2010) Potential of mycobacterial excretory secretory protein antigens (SEVA TB ES-31, ES-43, EST-6 and ES-20) as biomarkers to detect Mycobacterium Tuberculosis Bacilli. Indian J Clin Biochem 25: 15-19.
6. Shende N, Upadhye V, Kumar S, Gangane N, Harinath BC (2007) Study of M. Tuberculosis ES-31 and ES-20 antigen levels in different pathogenic grades of lymph node tuberculosis. Int J Tuberc Lung Dis 11: 222-226.
7. Gupta S, Shende N, Kumar S, Harinath BC (2005) Isolation of excretory secretory protein 6 kDa antigen (ES-6) and its seroreactivity in patients with different stages of pulmonary tuberculosis and healthy house hold contacts. Biomedical Research 16: 23-27.
8. Upadhye V, Roy SS, Shende N, Kumar S, Harinath BC (2007) Isolation of Mycobacterium tuberculosis protein antigens ES-31, ES-43 and EST-6 of diagnostic interest from Tubercle Bacilli by affinity chromatography. Indian J Exp Biol 45: 599-602.
9. Waghmare P, Wankhade G, Jena L, Harinath BC (2016) Excretory secretory proteins released during growth of Mycobacterium tuberculosis (H37Ra), with diagnostic potential in pulmonary and extra pulmonary tuberculosis. Mycobact Dis 6: 215.
10. Wankhade G, Majumdar A, Kamble P, Harinath BC (2011) Mycobacterial secretory SEVA TB ES-31 antigen, a chymotrypsin-like serine protease with lipase activity and drug target potential. Biomedical Research 22: 45-48.
11. Upadhye VI, Gomase AV, Kumar S, Harinath BC (2009) Isolation, characterization and kinetic studies on SEVA TB ES-31 antigen, a metallo-serine protease of interest in serodiagnosis. Indian J Tuberc 56: 22-29.
12. Pramanik J, Lodam AN, Reddy MVR, Narang P, Harinath BC (1997) Increased yield of excretory secretory antigen with thymoxine supplement in in vitro culture of tubercle bacilli. Indian J Tuberc 44: 185-190.
13. Nair ER, Banerjee S, Kumar S, Reddy MVR, Harinath BC (2001) Purification and characterization of a 31kDa mycobacterial excretory – secretory antigenic protein with a diagnostic potential in pulmonary tuberculosis. Indian J Chest Dis Allied Sc 43: 81-90.
14. Upadhye V, Majumdar A, Gomase A, Joshi D, Gangane N, et al. (2009) Inhibition of Mycobacterium tuberculosis secretion serine protease blocks bacterial multiplication both in axenic culture and in human macrophages. Scand J Infect Dis 41: 569-576.
15. Brady L, Brzozowski AM, Derewenda ZS, Dodson E, Norskov L, et al. (1990) A serine protease triad forms the catalytic centre of a triacylglycerol lipase. Nature 343: 767-770.
16. Fuji i R, Nakagawa Y, Hiratake J, Sogabe A, Sakata A (2005) Directed evolution of Pseudomonas aeruginosa lipase for improved amide-hydrolyzing activity. Protein Eng Des Sel 18: 93-101.
17. Tatsumo M, Mitsutoshi N, Hidemas K, Kosei K, Minora S, et al. (2003) Can lipases hydrolyse a peptide bond? Enzyme Microb Technol 32: 655-657.
18. Wankhade G, Hutke V, Waghmare P, Misra A, Varma S, et al. (2012) Inhibitory effect of isoniazid and orlistat combination on mycobacterial ES-31 serine protease in vitro and on the growth of Mycobacterium bacilli in axenic culture. Indian J Tuberc 59: 156-161.
19. Majumdar A, Wankhade G, Kamble P, Harinath BC (2011) Effect of HIV protease inhibitors and orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis. Indian J Tuberc 58: 4-10.